Trial reportEuropean journal of heart failure2022
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
Trial report in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities.European journal of heart failure · 2024Trial
- Retrospective evaluation of Selexipag monotherapy on pulmonary hemodynamics in newly diagnosed, treatment-naïve patients with chronic thromboembolic pulmonary hypertension prior to balloon pulmonary angioplasty.International journal of cardiology. Heart & vasculature · 2026Article
- Refining the Definition for "Low Risk" in Pulmonary Arterial Hypertension: Time to Reduce Morbidity and Mortality.JACC. Heart failure · 2026Article
- Phenotypic Clustering of Idiopathic Pulmonary Arterial Hypertension: Insights Into Pulmonary Vascular and Cardiometabolic Co-Morbidity Trajectories.Pulmonary circulation · 2026Article
- Diagnostic and management dilemmas in pulmonary hypertension.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Article
- Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies).Drugs - real world outcomes · 2026Article
- Synergistic Cardiopulmonary Protection of Endothelin Receptor Antagonists Combined With Soluble Guanylate Cyclase Agonists in High-Risk Coronary Syndrome With Pulmonary Hypertension.Reviews in cardiovascular medicine · 2026Article
- Attenuated benefit to vasodilators in patients with pulmonary arterial hypertension and high probability of heart failure with preserved ejection fraction.The European respiratory journal · 2025Article
- Pulmonary arterial hypertension treatment. A new era.International journal of cardiology. Congenital heart disease · 2025Review
- Pulmonary arterial hypertension with cardiopulmonary comorbidities: is it a unique phenotype?BMC pulmonary medicine · 2025Article
- Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUS.Advances in therapy · 2025Observational
- Impact of treatment escalation on rehospitalization among patients with pulmonary arterial hypertension.Scientific reports · 2025Article
- Ambrisentan Retains Its Pro-Autophagic Activity on Human Pulmonary Artery Endothelial Cells Exposed to Hypoxia in an In Vitro Model Mimicking Diabetes.Journal of cellular and molecular medicine · 2025Article
- Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox.International journal of cardiology. Congenital heart disease · 2025Review
- 2024 update in heart failure.ESC heart failure · 2025Review
- Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Impact of Comorbidities on Treatments and Outcomes of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.Canadian respiratory journal · 2025Article
- Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy.Biomarker research · 2024Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
14 authors at 12 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe number of pulmonary arterial hypertension (PAH) patients with comorbidities is increasing and there are limited data on response to PAH-targeted therapies in this population. These post hoc analyses explored the effect of selexipag in PAH patients with cardiovascular comorbidities in the GRIPHON study. METHODS AND
resultsRandomized patients (n = 1156) were classified using three methods: (i) by subgroups defined according to previously published comorbidity count and restrictive haemodynamic criteria: Subgroup A (<3 comorbidities and haemodynamic criteria met; n = 962) and Subgroup B (≥3 comorbidities and/or haemodynamic criteria not met; n = 144); comorbidities included body mass index ≥30 kg/m
conclusionSelexipag reduces the risk of a morbidity/mortality event vs. placebo irrespective of patient comorbidity status, suggesting that comorbidity status does not influence the treatment effect of selexipag.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.